ROSIGLITAZONE MALEATE AND GLIMEPIRIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rosiglitazone Maleate And Glimepiride, and when can generic versions of Rosiglitazone Maleate And Glimepiride launch?
Rosiglitazone Maleate And Glimepiride is a drug marketed by Teva Pharms Usa and is included in one NDA.
The generic ingredient in ROSIGLITAZONE MALEATE AND GLIMEPIRIDE is glimepiride; rosiglitazone maleate. There are sixteen drug master file entries for this compound. Additional details are available on the glimepiride; rosiglitazone maleate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROSIGLITAZONE MALEATE AND GLIMEPIRIDE?
- What are the global sales for ROSIGLITAZONE MALEATE AND GLIMEPIRIDE?
- What is Average Wholesale Price for ROSIGLITAZONE MALEATE AND GLIMEPIRIDE?
Summary for ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | ROSIGLITAZONE MALEATE AND GLIMEPIRIDE at DailyMed |
Recent Clinical Trials for ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 3 |
| Canadian Heart Research Centre | Phase 3 |
See all ROSIGLITAZONE MALEATE AND GLIMEPIRIDE clinical trials
